Rejected from IEEE TPAMI? The 6 Best Venues to Submit Next

Your closest matches depend on whether your contribution is vision methodology, a learning system, or a contribution that stands better on its own at a conference. The shortlist below covers all three routes.

Source: JCR 2024, Springer and IEEE and Elsevier author guidelines and open-access pages, journal acceptance-rate listings (accessed June 2026).

Run a TPAMI manuscript fit check before you pick a venue, so you route on the actual rejection reason rather than on prestige alone.

The single most important decision after a TPAMI rejection is not which journal sits one tier down. It is whether your paper wants to be a journal paper at all.

First, decide the journal-versus-conference route. TPAMI is a journal that rewards comprehensiveness: deeper theory, exhaustive ablations, multiple datasets, stronger reproducibility. A top conference rewards a sharp, self-contained idea on a fixed deadline. If TPAMI rejected you specifically because the journal-extension delta over your CVPR or ICCV paper was thin, the honest read is that the contribution is conference-shaped.

In that case the next venue is CVPR, ICCV, ECCV (for vision) or NeurIPS, ICML (for learning), not a lower-tier journal where the same "this is just the conference paper" objection will resurface.

If it should stay a journal, step down by fit, not just by JIF. The first-choice journal cascade for vision methodology is IJCV, then IEEE TIP. For neural-network and learning-systems contributions, IEEE TNNLS is the natural next target. For pattern-recognition and classification work that is strong but broader than TPAMI's methodology-only bar, Pattern Recognition and CVIU are the realistic next tier. Each step trades a little selectivity for a better scope match, which matters more than the raw IF number.

Match the rejection reason to the next venue. A "limited novelty for TPAMI" reject often clears at IJCV or TIP, where a strong, well-evaluated method is judged on its own terms rather than against TPAMI's "field-defining" bar. A "weak experimental evaluation" reject will follow you to every serious venue, so fix the benchmarks before you move. A "scope or fit" reject is the easiest to act on: the work is good, it just needed a different editorial home.

Source: TPAMI author guidance plus Springer, IEEE, and Elsevier venue scope pages (accessed June 2026).

In our pre-submission review work with IEEE TPAMI submissions, the rejections we see most often cluster into four named rejection patterns. Each is specific, testable against your own manuscript, and tied to a concrete component a reviewer can point at. In our review of TPAMI manuscripts, these four map to a recurring editorial expectation: a journal-scale, fully-evaluated contribution. TPAMI editors consistently screen for them before a paper ever reaches its three reviewers, and across the TPAMI manuscripts we pre-screen the same four account for most desk-stage rejections.

The conference-extension delta is too thin. This is the most common pattern in the TPAMI submissions we review. The paper is a competent extension of a CVPR, ICCV, or NeurIPS version, but the new material is an extra dataset and two added figures rather than a genuine methodological advance. TPAMI policy expects at least 30 percent new material that meaningfully extends the results.

In our pre-submission reviews of TPAMI manuscripts, we flag this when the journal version's novelty over the conference paper cannot be stated in one sentence that names a new method, a new theoretical result, or a new analysis, rather than "more experiments." If your delta is mostly appendix material and an expanded related-work section, a reviewer will say the contribution is incremental.

The benchmark and state-of-the-art comparison is incomplete. TPAMI editors screen the experimental section closely, and reviewers expect comprehensive comparison against current baselines on standardized benchmarks (ImageNet, COCO, ADE20K, and the datasets standard for your subarea), not a favorable subset. We repeatedly see TPAMI submissions that compare against methods two years stale, omit a strong recent baseline, or report a single headline number without the ablation study that isolates where the gain comes from.

A leaderboard result with no technical explanation of why the method works, and no evidence it generalizes beyond one dataset or one model setup, reads as an engineering result rather than a TPAMI contribution.

The ablation study does not isolate the claimed contribution. Across our TPAMI pre-submission reviews, a recurring failure is a methods section that proposes three components but an experimental section that only reports the full system. Reviewers cannot tell which part carries the improvement, so they cannot credit the novelty.

If your ablations do not turn each claimed contribution on and off independently, and report the effect size of each, the paper looks like a combination of known strategies rather than a new method, which is one of the most quoted TPAMI reject lines.

Reproducibility and presentation undercut a sound method. TPAMI is a long-format journal, and reviewers read the whole manuscript closely. We flag submissions where the code and trained-model release is vague or absent, where key hyperparameters and training details are missing from the methods, or where the figures are dense conference-style panels that do not carry a journal-length argument.

A paper that is over the page limit and incurs overlength charges (IEEE assesses these in addition to any open-access fee) without earning the extra length with content also signals a manuscript that was not shaped for the journal.

Do not just blast the same PDF down the ladder. A TPAMI rejection that cited weak evaluation or a thin novelty delta will produce the same outcome at IJCV or TIP, because those reviewers apply a similar standard and you may even draw the same reviewer pool. The fix is not a formatting pass.

Be honest about which kind of rejection you got. If reviewers questioned the contribution itself (novelty, depth, significance), the paper needs real work: a sharper method, a new theoretical result, or a clearer journal-scale argument before it is ready for any top venue. If the rejection cited scope or fit, the paper may be ready as-is for a better-matched journal. If it cited benchmark coverage or missing ablations, run those experiments first; they will surface at the next journal too.

One more honest call: if two of three reviewers questioned the novelty, an appeal will not reverse a judgment call, and the conference route may serve the paper better than forcing it into a journal it was never shaped for.